Drug resistance interpretation: PR

HIVDB 9.5.1 (2023-11-05)

PI Major Mutations: None
PI Accessory Mutations: None
PR Other Mutations: V11V • T12K • I13V • L19LI • K20I • M36I • R41K • K45KR • L63LI • H69K • K70Q • V82I • L89M

Protease Inhibitors	
atazanavir/r (ATV/r)	Susceptible
darunavir/r (DRV/r)	Susceptible
lopinavir/r (LPV/r)	Susceptible

PR comments

Other

- **V11I/L** are relatively non-polymorphic accessory mutation selected in persons receiving DRV. V11L is a nonpolymorphic PI-selected mutation associated with reduced in vitro DRV susceptibility when it occurs in combination with other PI-resistance mutations.
- **K20I** is the consensus amino acid in subtype G and CRF02_AG. In subtypes B and C, **K20I** is a PI-selected mutation of uncertain effects on currently used PIs.
- **V82I** is a highly polymorphic mutation that is not selected by PIs. It is the consensus amino acid in subtype G viruses.

Mutation scoring: PR

HIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for PI.

Drug resistance interpretation: RT

HIVDB 9.5.1 (2023-11-05)

NRTI Mutations: None
NNRTI Mutations: G190GA
RT Other Mutations: P4T • E6D • K20R • V35T • V60I • K122E • D123S • K173T • Q174K • I180IV • Q207A • R211N • D250E • S251D • A272P • T286A • I293V • F294T • E297R • I309IL • E312ED

Nucleoside Reverse Transcriptase Inhibitors	
abacavir (ABC)	Susceptible
zidovudine (AZT)	Susceptible
emtricitabine (FTC)	Susceptible
lamivudine (3TC)	Susceptible
tenofovir (TDF)	Susceptible

Non-nucleoside Reverse Transcriptase Inhibitors	
doravirine (DOR)	Susceptible
efavirenz (EFV)	Intermediate Resistance
etravirine (ETR)	Potential Low-Level Resistance
nevirapine (NVP)	High-Level Resistance
rilpivirine (RPV)	Low-Level Resistance

RT comments

NNRTI

- **G190A** is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It does not significantly reduce susceptibility to RPV, ETR, or DOR.
- This virus is predicted to have low-level reduced susceptibility to **RPV**. The use of the combination of CAB/**RPV** should be considered to be relatively contraindicated.

Mutation scoring: RT

HIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for NRTI.

Drug resistance mutation scores of NNRTI: Download CSV

Rule	DOR	EFV	ETR	NVP	RPV
G190GA	0	45	10	60	15